ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY25 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY25 earnings guidance on Friday. The company provided EPS guidance of $6.12-6.49 for the period, compared to the consensus EPS estimate of $5.56. The company issued revenue guidance of $756-776 million, compared to the consensus revenue estimate of $724.88 million.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $6.74 during midday trading on Friday, reaching $61.32. 322,017 shares of the company’s stock traded hands, compared to its average volume of 199,757. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -111.54 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The stock has a 50 day moving average of $57.06 and a 200 day moving average of $58.13.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, February 28th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.22. The business had revenue of $190.60 million during the quarter, compared to analysts’ expectations of $175.36 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business’s quarterly revenue was up 44.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.04 earnings per share. As a group, equities research analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,300 shares of company stock worth $584,009 over the last quarter. 12.70% of the stock is currently owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.